|3rd September 2020||Paul Sean Little||5,763||Payment by withholding||$3.54||$20,401.02|
|14th July 2020||Keith J Sullivan||500,000||Grant/award etc.||$0.00|
|5th June 2020||Hove Caroline F. Van||27,717||Grant/award etc.||$0.00|
|5th June 2020||Kevin C Oboyle||27,717||Grant/award etc.||$0.00|
|5th June 2020||Mary Fisher||27,717||Grant/award etc.||$0.00|
|5th June 2020||Philippe Schaison||27,717||Grant/award etc.||$0.00|
|5th June 2020||Nicholas Simon||27,717||Grant/award etc.||$0.00|
|5th June 2020||Keith J Sullivan||27,717||Grant/award etc.||$0.00|
|29th May 2020||Kevin C Oboyle||17,998||Grant/award etc.||$0.00|
|21st May 2020||Kevin C Oboyle||1,376||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
Sientra, Inc. engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra,. AlloX2, Dermaspan, Softspan and BIOCORNEUM.